Diagnostic Value of Serum D-Dimer for Detection of Gallbladder Carcinoma

Kong, Weihao; Zhang, Li; An, Ran; Yang, Mingwei; Wang, Hao

doi:10.2147/cmar.s272116

Cited by 6 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inappropriate activation of both coagulation and fibrinolysis is usually discovered in carcinoma patients, especially in those with metastatic disease (17)(18)(19)(20). Plasma D-dimer, the smallest cross-linked protein produced in the proteolytic process, is a marker for detecting malignancy and is of great significance for the clinical exclusion of tumor-related thrombosis (21).…”

Section: Introductionmentioning

confidence: 99%

“…Plasma D-dimer, the smallest cross-linked protein produced in the proteolytic process, is a marker for detecting malignancy and is of great significance for the clinical exclusion of tumor-related thrombosis (21). Previous studies have shown the predictive role of plasma D-dimer in many malignancies treated with chemotherapy, including lung cancer (22)(23)(24)(25)(26), colorectal cancer (27), gallbladder carcinoma (20), and breast cancer (28). However, whether pretreatment D-dimer can predict therapeutic efficacy and prognosis in advanced NSCLC patients receiving ICI treatment remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study

Li¹,

Lu²,

Zhang³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background: Plasma D-dimer is of great significance for the clinical exclusion of tumor-related thrombosis. Previous studies have shown its predictive role in non-small cell lung cancer (NSCLC) treated with chemotherapy. However, whether pretreatment D-dimer could predict the efficacy and prognosis in NSCLC patients treated with immune checkpoint inhibitors (ICIs) remains unclear.Methods: Advanced NSCLC patients treated with ICIs at the Chinese PLA General Hospital between January 2015 and March 2019 were enrolled. Patients were divided into a pretreatment normal D-dimer group (≤0.5 μg/mL) and high D-dimer group (>0.5 μg/mL). Optimization-based approach was applied to balance baseline covariates between the 2 groups, including age, sex, histological type, smoking history, stage, Eastern Cooperative Oncology Group Performance Status (ECOG PS), lines of treatment, ICI drugs, brain metastasis, treatment type, and D-dimer levels. Kaplan-Meier analysis and Cox proportional hazards model were used for analyzing survival data, including progression-free survival (PFS, the time from initial ICI treatment to PD or death), overall survival (OS, the time between initial ICI treatment and death), and hazard ratio (HR). Follow-up of all patients was performed by searching electronic medical records and counseling telephone. The follow-up cut-off date was July 6, 2020.Results: This study included 277 advanced NSCLC patients. Among the enrolled patients, 23.1% were female, 64.6% had non-squamous cell lung cancer, and 79.4% were stage IV. Univariate and multivariate analysis showed that pretreatment high D-dimer levels were independently associated with shortened PFS and OS (P<0.01). Subgroup analysis confirmed that pretreatment high D-dimer levels were associated with poor prognosis in most subsets. After balancing baseline covariates between the high D-dimer group and normal D-dimer group, the results indicated that patients with pretreatment high D-dimer levels had significantly shorter PFS [median: 6.4 vs. 11.5 months; HR, 1.70; 95% confidence ratio (CI): 1.25-2.37; P<0.001] and OS (median: 12.7 vs. 30.4 months; HR, 2.29; 95% CI: 1.54-3.41; P<0.001) than those with pretreatment normal D-dimer levels.Conclusions: Pretreatment plasma D-dimer could serve as a convenient prognostic biomarker for advanced NSCLC patients receiving ICI treatment. Patients with pretreatment high D-dimer levels may have poor PFS and OS.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study

Li¹,

Lu²,

Zhang³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…In addition, the use of coagulation disorder in the diagnosis of some malignant tumors has also been reported. For example, APTT and platelet distribution width (PDW used individually or in combination showed good predictive values for nasopharyngeal carcinoma, while APTT, FIB, and DD2 were significantly associated with nasopharyngeal carcinoma metastasis [ 25 ]; there was an independent correlation between abnormally increased FIB and prostate cancer sensitivity [ 26 ]; serum DD2 was a potential marker for the diagnosis of gallbladder cancer, and DD2 combined with CA199 had excellent diagnostic value for this cancer (AUC = 0.920) [ 27 ]. As in other malignant tumors, some CC parameters have been reported to have diagnostic value for PC.…”

Section: Discussionmentioning

confidence: 99%

Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study

Jiaao,

Wanli,

Kai

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Background In recent years, conventional coagulation (CC) and thromboelastography (TEG) parameters have been reported to be closely related to the progression of pancreatic cancer (PC). However, the potential utility of these parameters in differentiating benign and malignant pancreatic diseases is still unclear. Objectives A retrospective study was conducted to evaluate the efficacy of coagulation parameters in differentiating pancreatic cancer/early stage pancreatic cancer (EPC, TNM stages I and II) from benign control conditions, and to further explore whether coagulation parameters could improve the differential value of CA199. Methods Receiver operating characteristic (ROC) curves and logistic regression analysis were used to identify the diagnostic value of each coagulation parameter or combination of parameters. Results Compared with benign pancreatic disease (BPD), patients with pancreatic malignant tumors had significant coagulation disorders, specifically manifested as abnormal increases or decreases in several CC and TEG parameters (such as activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (DD2), K time, R time, Angle, maximum amplitude (MA), coagulation index (CI), and Ly30). In the training group, ROC curve showed that FIB, DD2, Angle, MA, and CI had favorable efficacy at differentiating PC or EPC from BPD (for PC, AUC = 0.737, 0.654, 0.627, 0.602, 0.648; for EPC, AUC = 0.723, 0.635, 0.630, 0.614, 0.648). However, several combined diagnostic indicators based on FIB, DD2 and CI failed to outperform the individual coagulation indexes in diagnostic efficiency. Combinations of certain coagulation indexes with CA199 outperformed CA199 alone at identifying PC or EPC, especially FIB + CA199 (for PC, AUC = 0.904; for EPC, AUC = 0.905), FIB + DD2 + CA199 (for PC, AUC = 0.902; for EPC, AUC = 0.900), FIB + CI + CA199 (for PC, AUC = 0.906; for EPC, AUC = 0.906), and FIB + DD2 + CI + CA199 (for PC, AUC = 0.905; for EPC, AUC = 0.900). The results from a validation set also confirmed that these combinations have advantageous diagnostic value for PC and EPC. Conclusions A significant hypercoagulable state was common in PC. Some CC and TEG parameters are valuable in the differential diagnosis of benign and malignant pancreatic diseases. In addition, coagulation indexes combined with CA199 can further enhance the differential diagnosis efficacy of CA199 in PC and EPC.

show abstract

“…[6] The correlation between PLR, NLR, and D-dimer (D-D) and the prognosis of solid tumors has been confirmed, such as for gastric carcinoma, colorectal neoplasms, liver tumors, breast carcinoma and bile duct carcinoma. [7][8][9] In recent years, studies have found that use of inflammation-related prognostic indicators and blood coagulation fibrinolysis system markers (D-D) can predict the survival and prognosis of patients with esophageal carcinoma, colorectal carcinoma, gastric carcinoma, ovarian carcinoma and NSCLC. [10][11][12] However, whether D-D before treatment and combined PLR and NLR can predict the shortterm efficacy and prognosis of SCLC sufferers is unclear.…”

Section: Introductionmentioning

confidence: 99%

D-D and PLR, NLR combined forecasting first-line treatment: The short-term curative effect and prognosis of patients with SCLC

Hu,

Chen,

Sun

et al. 2023

Medicine

View full text Add to dashboard Cite

The aim of this study was to evaluate the difference in D-dimer (D-D) combined with the platelet lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) before treatment in small cell lung cancer (SCLC) patients receiving first-line treatment and to analyze the efficacy and prognosis. We retrospectively collected the records of SCLC patients treated in our hospital from February 2019 to January 2023 and finally included 100 patients. A binary logistic regression analysis method was applied to analyze the relationship between D-D, PLR, and NLR and short-term efficacy. Univariate and multivariate Cox regression analyses were utilized to estimate the individual effect of plasma parameters on progression-free survival (PFS). The optimal cutoff values of D-D, PLR, and NLR for predicting survival outcome were determined by receiver operating characteristic curve analysis. Kaplan–Meier survival analysis was utilized to examine the correlation between D-D, PLR, and NLR the prognosis of SCLC patients. PLR was associated with a short-term curative effect in patients with SCLC (odds ratio: 0.326, 95% confidence interval [CI]: 0.135 0.790). Univariate Cox regression showed that D-D (hazard ratio [HR]: 0.495, 95% CI: 0.323–0.758), PLR (HR:0.420, 95% CI: 0.269–0.655) and NLR (HR: 0.407, 95% CI: 0.263–0.630) were associated with PFS in SCLC patients (P < .05). Multivariate Cox regression analysis showed that PLR (HR: 2.395, 95% CI: 1.468–3.906) and NLR (HR: 2.148, 95% CI: 1.319–3.499) correlated significantly with PFS (P < .05). The optimal cutoff values of D-D, PLR and NLR for predicting PFS were 0.88 mg/L (65.4% and 68.7%), 195.44 (61.5% and 81.2%) and 3.63 (63.5% and 81.2%), respectively, and the corresponding area under receiver (AUC) operating characteristic curve 0.691 (95% CI: 0.587–0.795), 0.721 (95% CI: 0.620–0.822) and 0.714 (95% CI: 0.614–0.815). When D-D was used in combination with PLR or NLR, the corresponding AUCs were 0.737 (95% CI: 0.640–0.835) and 0.761 (95% CI: 0.667–0.855). Pretreatment PLR is an independent predictor of short-term efficacy in SCLC patients. Pretreatment D-D, PLR and NLR are potential biochemical markers for predicting the prognosis of SCLC patients treated with first-line treatment. When D-D is combined with PLR and NLR, it shows stronger predictive ability.

show abstract

Diagnostic Value of Serum D-Dimer for Detection of Gallbladder Carcinoma

Cited by 6 publications

References 28 publications

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study

Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study

D-D and PLR, NLR combined forecasting first-line treatment: The short-term curative effect and prognosis of patients with SCLC

Contact Info

Product

Resources

About